Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma
Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma
whose are treated with cytoreductive therapy and stem cell transplant.
Observational
Observational Model: Case Control, Time Perspective: Prospective
progression-free disease and overall toxicity in myeloma multiple
In patients treated with cytoreductive therapy following by stem cell transplant and that received zoledronic acid by 2 years,they were evaluable for assess antitumor effect of zoledronic acid
3 years
No
Agustin Aviles, MD
Principal Investigator
Instituto Mexicano del Seguro Social
Mexico:Mexican Institute of Social Security
kitty1
NCT01234129
June 2002
December 2009
Name | Location |
---|